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Background: Microscopy and antigen detecting rapid diagnostic tests are the diagnostic tests of choice in
management of clinical malaria. However, due to their limitations, the need to utilize more sensitive methods such as
real-time PCR (qPCR) is evident as more studies are now utilizing molecular methods in detection of malaria. Some of
the challenges that continue to limit the widespread utilization of qPCR include lack of assay standardization, assay
variability, risk of contamination, and the need for cold-chain. Lyophilization of molecular assays can overcome some
of these limitations and potentially enable widespread qPCR utilization.
Methods: A recently published multiplex malaria qPCR assay was lyophilized by freezing drying into Sample-Ready™
format (MMSR). MMSR assay contained all the required reagents for qPCR including primers and probes, requiring
only the addition of water and sample to perform qPCR. The performance of the MMSR assay was compared to the
non-freeze dried, “wet” assay. Stability studies were done by maintaining the MMSR assays at four different ambient
temperatures of 4°C, room temperature (RT), 37°C and 42°C over a period of 42 days, tested at seven-day intervals.
Plasmodium falciparum and Plasmodium vivax DNAs were used for analysis of the MMSR assay either as single or mixed
parasites, at two different concentrations. The CT values and the standard deviations (SD) were used in the analysis of
the assay performance.
Results: The limit of detection for the MMSR assay was 0.244 parasites/μL for Plasmodium spp. (PLU) and P. falciparum
(FAL) assay targets compared to “wet” assay which was 0.39 and 3.13 parasites/μL for PLU and FAL assay targets,
respectively. The MMSR assay performed with high efficiencies similar to those of the “wet” assay and was stable at
37°C for 42 days, with estimated shelf-life of 5 months. When used to analyse field clinical samples, MMSR assay
performed with 100% sensitivity and specificity compared to the “wet” assay.
Conclusion: The MMSR assay has the same robust performance characteristics as the “wet” assay and is highly stable.
Availability of MMSR assay allows flexibility and provides an option in choosing assay for malaria diagnostics depending
on the application, needs and budget.Background
Accurate and prompt diagnosis is essential for timely
and appropriate treatment of malaria. The World Health
Organization (WHO) guidelines for the treatment of
malaria recommend parasitological confirmation of all
suspected cases before treating [1]. Although microscopy
remains the gold standard for malaria diagnosis [2,3], the* Correspondence: edwin.kamau@us.army.mil
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unless otherwise stated.use of malaria antigen detecting rapid diagnostic tests
(mRDTs) as an alternative diagnostic method has increased
over the years and provided an avenue through which
access to parasite-based diagnosis, specifically in areas
where good quality microscopy cannot be maintained, can
be expanded [4]. However, both microscopy and mRDTs
have many limitations. Notably, both methods have poor
sensitivity and are highly variable [5-7]. Molecular assays
that detect Plasmodium-specific nucleic acid sequences
are increasingly being used in the detection and analysis of
malaria to overcome limitations associated with microscopy
and mRDTs. Assays such as real-time PCR (qPCR) are
more sensitive and specific than microscopy and mRDTsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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quantification of malaria parasites [8-13]. Most of the
malaria qPCR assays target the multicopy 18S ribosomal
RNA (rRNA) genes [14] with detection limits ranging
from 0.002 to 30 parasites/μL [10,14].
Currently, there is lack of consensus on how to best
perform and interpret qPCR assays [15]. Real-time PCRs
can be performed in the background of different PCR
master mixes, variable chemistry, reagents, and platforms,
all which can affect the sensitivity and reproducibility of
the assay. Furthermore, PCR requires specialized training
and proper implementation of quality control measures,
including need for a clean room or separate master
mix preparation area. There is always the concern of
false-positive results due to contamination or false-negative
especially if proper internal controls are not in place.
Real-time PCR also requires cold chain which can be ex-
pensive, highly variable and time consuming. Kamau et al.
[16] recently described development of a multiplex qPCR
assay for detection of Plasmodium genus target, and
species specific Plasmodium falciparum, Plasmodium vivax
targets as well as human RNaseP gene as an endogenous
control. In addition to containing all the characteristics that
makes qPCR an increasingly attractive diagnostic tool, the
multiplex assay described was designed to be amenable to
high throughput with drastically reduced costs.
This study describes further optimization of the recently
published multiplex qPCR assay [16] which was lyophilized
into a Sample-Ready™ format (BioGX, Birmingham, AL,
USA). This format contains all the required components
for qPCR; requiring only the addition of water and sample
for qPCR analysis. Lyophilization of qPCR assays has many
advantages and is important in mitigating some of the
qPCR limitations. The Malaria Multiplex Sample-Ready™
(MMSR) assay was formulated with an optimized, highly
sensitive chemistry with primers and probes for genus
(Plasmodium spp. [PLU]) and species specific targets
(P. falciparum [PAL] and P. vivax [VIV]) as well as human
RNaseP gene. The performance characteristics of MMSR
assay and stability studies are presented.
Methods
Samples
Samples used in this study were obtained from a blood col-
lection protocol between 2010–2012 at the KEMRI/ Walter
Reed Project, Kombewa District Hospital which is located
in the Kombewa district, Kisumu County in western Kenya.
The study was approved by the Ethical Review Committee
of the Kenya Medical Research Institute (KEMRI), Nairobi,
Kenya, and the Walter Reed Army Institute of Research
(WRAIR) Institutional Review Board (IRB), Silver Spring,
MD, USA. The study protocol numbers are KEMRI SSC
NO. 2008 and WRAIR 1720. This study was conducted in
accordance with GCP principles and instructions from theDepartment of Defense and the Department of the Army.
All potential study subjects provided written informed
consent before screening and enrollment and had to
pass an assessment of understanding.Plasmodium falciparum reference reagent
The WHO international standard for P. falciparum
DNA nucleic acid amplification technology (NAT)
assays, obtained from the National Institute for Biological
Standards and Control (NIBSC; Hertfordshire, UK)
was used as the calibration reference reagent for the
Plasmodium spp. and P. falciparum assays. The NIBSC
standard consists of a freeze-dried preparation of whole
blood collected by exchange transfusion from a patient
infected with P. falciparum. Following NIBSC recommen-
dations, this lyophilized material was suspended in 500 μL
of sterile, nuclease-free water to a final concentration of
1×109 IU/mL, which corresponds to a parasitaemia of 9.79
parasites/100 red blood cells [17,18]. The parasite density
of the NIBSC standard after reconstitution was estimated
to be 469,920 parasites/μL, based on the average red blood
cell count (from uninfected donor) of 4.8×106 RBC/μL.
Unless otherwise indicated, fresh uninfected whole blood
was used as a diluent to prepare serial dilutions. The
uninfected whole blood was obtained from donors from
Washington DC metropolitan area under WRAIR approved
protocol. After reconstitution, genomic DNA was extracted
with the EZ1 DNA blood kit on the EZ1 Advanced XL
automated sample purification system (Qiagen, Valencia,
CA, USA) as recommended by the manufacturer.Design and manufacturing of freeze dried Sample-Ready™
assays
The designing, development and testing of the “wet”
qPCR assay have been previously described [10,16].
BioGX Inc, a molecular assay manufacturing company
based in Birmingham, AL, USA was contracted to custom
manufacture the MMSR assay using their proprietary
procedures and formulations. BioGX Inc was supplied
with all the primers, probes, and Plasmodium DNA for
assay testing and optimization. They performed additional
testing to optimize the MMSR assay using BioGX Inc
master mix that is included in the final lyophilized
Sample-Ready™ format. The MMSR assays were manufac-
tured either as pellets or cakes in eight-well strip tubes or
in 96-well plates, with each well containing all reagents
for a 5-μL assay. The assays were sealed in water and
lightproof pouches containing desiccant and either
four-, six-well, eight-well strip tubes or one 96-well plate,
which was either half or fully loaded. The MMSR assay
was custom designed for use on an Applied Biosystems
7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA).
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Real-time qPCR amplifications and measurements for
the “wet” assay were performed as previously described
using QuantiTect Multiplex PCR Master Mix (Qiagen,
Valencia, CA, USA) [16]. The qPCR amplification and
measurements for MMSR assay were performed as follows:
The assay was prepared by just adding 5 μL water to each
test, and then adding 1 μL DNA (or water for non-template
control (NTC)). The thermal profile used for the MMSR
assay was as follows: 2 min at 95°C; 45 cycles of 10 sec at
95°C; 60 sec 59°C.
Limit of detection (LoD) studies
The determination of the LoD began with dilution series.
Reconstituted NIBSC standard or P. vivax sample were
spiked into uninfected whole blood followed by a series
of five-fold dilutions over five-fold range inclusive of the
first dilution. This was followed by two-fold dilutions.
DNA was extracted from each serially diluted sample
using Qiagen EZ1 DSP DNA blood kit on EZ1 Advanced
XL automated sample purification system. Extracted
DNA samples were analysed using MMSR PCR assay
with each sample tested in duplicate or triplicate. RNaseP
assay was analysed in all the reactions. Reactions containing
P. falciparum DNA (NIBSC standard) samples were
analysed using Plasmodium spp. and P. falciparum
assays whereas for the reactions containing P. vivax
DNA sample, only P. vivax assay was used for analysis.
The lowest concentration of DNA that yielded positive
test results was considered the LoD.
Stability studies
The stability of MMSR assay was estimated using
accelerated aging techniques with elevated temperatures
over a period of 42 days (estimated 1.5 months), analysed
at intervals of seven days, referred to as time points. The
ambient storage temperatures tested (test conditions)
were 4°C (the storage conditions recommended by the
manufacturer), room temperature (RT, set at 22°C and
monitored frequently), 37°C and 42°C. For the 4°C
ambient temperature, the assays were kept in the
refrigerator with monitored temperature and for the
RT, the assays were kept in clean area in the laboratory.
For the elevated temperatures, two different incubators
set at 37°C and 42°C were used for the entire period of
study with continuous monitoring of the temperatures.
For analysis, qPCR assays were performed every seven
days. At the beginning of the study on D0, the number of
assays required for testing at 4°C, RT, 37°C or 42°C on D7,
D14, D21, D28, D35, and D42 were estimated. These
MMSR assays were then kept at each ambient temperature
conditions in zip-lock double bags with desiccants. On D7
and subsequent days, samples required for testing were
retrieved and qPCR assay performed. The genomic DNAused in these experiments contained either P. falciparum
only, P. vivax only or a mixture of both P. falciparum and
P. vivax genomic DNAs. Two different concentrations
of genomic DNA were used; high and low. The high
concentration contained ~100 parasite/μL whereas the
low contained ~20 parasite/μL. Each assay was performed
in triplicate and CT values were obtained. The standard
deviation (SD) of the CT values was used to assess
the precision of the replicates as well as performance of
the assays in the different conditions tested, including
different ambient temperatures and period which the assay
was stored. The longest duration that the thermostabilized
PCR maintained its activity was calculated as described by
Clark [19]:
Age of the thermostabilized PCR tubes = 1.5 months at
37°C or 42°C
Ambient temperature RT = 22°C
Q10 = 1.8
Acceleration factor at 37°C (based on 15°C temperature
difference): (1.8)1.5 = 2 .41
Acceleration factor at 42°C (based on 20°C temperature
difference): (1.8)2.0 = 3.24
Length of time at elevated temperature = 1.5 months
Estimation of shelf life:
Accelerated age = age × acceleration factor (at 37°C)
1.5 months × 2.41 = 3.615 months
Shelf life = accelerated age + actual age
3.615 + 1.5 = 5.115 months
Accelerated age = age × acceleration factor (at 42°C)
1.5 months × 3.24 = 4.86 months
Shelf life = accelerated age + actual age
8.1 + 2.5 = 6.36 months
Results
Performance characteristics of the MMSR assay
The initial performance characteristics of the MMSR
assay were compared to the “wet” assay using NIBSC
standard at three different concentrations as shown in
Table 1. The assays were run in duplicate. The MMSR
assay performed slightly better than “wet” assay by
detecting the parasite DNA at lower CT values. The
sensitivity of the MMSR was compared to the “wet”
assay by performing LoD experiments. The LoD for the
MMSR assay was 0.244 parasites/μL for PLU and FAL
targets compared to “wet” assay which was 0.39 and 3.13
parasites/μL for PLU and FAL targets, respectively.
Lyophilization process improved the performance of
the FAL assay, improving the LoD by ~ log from 3.13
parasites/μL to 0.244 parasites/μL. To evaluate the
efficiency of MMSR assay, PLU, FAL and VIV plasmid
DNAs were five-fold serially diluted five times and
analysed in three replicates as previously described [16].
The MMSR assay performed with high efficiency and
Table 1 Detection characteristics of MMSR assay in
comparison to “wet” assay
MMSR assay Wet assay Parasite/μL
CT Mean CT SD CT Mean CT SD
PLU assay 18.55 0.013 19.78 0.191 78240
FAL assay 20.07 0.031 20.85 0.055
RNaseP assay 24.13 0.083 30.09 0.081
PLU assay 20.73 0.092 22.17 0.227 15648
FAL assay 22.23 0.054 23.62 0.338
RNaseP assay 24.52 0.185 29.57 0.082
PLU assay 23.58 0.029 24.89 0.616 3129
FAL assay 24.93 0.001 26.06 0.029
RNaseP assay 25.37 0.055 29.43 0.492
NIBSC standard DNA was five-fold serially diluted times. The performance of
MMSR assay was compared to the “wet” assay. The performance of the MMSR
assay was comparable to that of the “wet” assay for the three assay
targets tested.
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previously reported [16]. The PLU assay had efficiency of
99%, FAL assay 100% and VIV assay 99%, each with
R2 values of 0.99 and SD replicates <0.167.
MMSR stability studies
The stability of MMSR assay was tested by comparing the
performance of the assay at four different ambient
temperatures over 42 days. The MMSR assay was
manufactured in eight-well strip tubes or in 96-well
plates with caps, and then sealed in a pouch, which
contains desiccants. In addition, each pouch which
contains the MMSR assays was put in zip-lock double
bags with additional desiccants to minimize the possibility
of moisture impacting the outcome of the study. Analyses
of the MMSR assay using mixed DNA, which contained
both P. falciparum and P. vivax, are presented here in
detail. When the DNA at high concentration was analysed,
the MMSR assay performed with high precision in all
replicates and in all conditions tested (Additional file 1).Figure 1 Performance of PLU assay in different ambient temperatures.
D7. The condition which the assay was stored did not impact the performancEach individual assay targets, PLU, FAL, VIV and RNaseP
were analysed by comparing the CT values for each
assay target, at each time point tested, for each condition.
For example, on D7, PLU assay had CT ± SD of 26.47 ±
0.056 at 4°C, 26.45 ± 0.18 at RT, 26.36 ± 0.04 at 37°C and
26.37 ± 0.078 at 42°C (Figure 1). These values had high
precision with CT mean ± SD 26.41 ± 0.06. This indicates
on D7, the different ambient temperatures tested did not
have an effect on the performance of the PLU target when
used for analysis of DNA at high concentrations. Figure 2A
shows the CT mean ± SD for all individual assay targets
for all test conditions at the different time points using
DNA at high concentrations. As shown for D7, data
obtained indicate that at each time point tested, each assay
target performed equally well regardless of the ambient
temperature. When the stability of MMSR assay was ana-
lysed using DNA at low concentrations, the performance
of the assay indicated slight degradation at 37°C and 42°C
on D21, D28 and D35 (Additional file 2). At 37°C, only
one of the three replicates of VIV target was successfully
amplified on D21 and D28. At 42°C, the VIV target failed
to amplify on D28 and on D35, FAL and VIV assays failed.
What is intriguing however, the four assay targets
performed well on D42 at 42°C like they did on D0. The
degradation is clearly indicated for specific target(s) since
a mixture of DNA was loaded in the assay where some
target(s) amplified while others failed to amplify in the
same reaction. Figure 2B shows the CT mean ± SD for all
the individual assay targets for all test conditions at the
different time points using DNA at low concentrations.
Here, the SD values were larger compared to those
obtained when DNA at higher concentrations was used
(Additional file 1, Figure 2A), especially for FAL assay
which performed with the least precision. MMSR assay
performance was also analysed in all test conditions using
single DNA of P. falciparum or P. vivax. The MMSR assay
demonstrated high stability in all conditions tested when
analysed with P. vivax DNA, both high and low concen-
trations. The degradation of the MMSR assay seen whenData showing CT values obtained in all ambient temperatures tested on
e of the assay. Assay was analysed using DNA at high concentration.
Figure 2 Performance of individual assay targets over time. Data showing the CT mean ± SD for individual assay targets for all test conditions.
Panel A shows data using DNA at high concentrations and panel B shows data using DNA at low concentration. For example, on D7, PLU assay is
showing mean CT values and the SD for each ambient temperature tested on that day. Low SD indicates different ambient temperatures which the
assay was stored in did not impact the performance of the assay using either low or high DNA concentration. For FAL assay however, at low DNA
concentration, the SD was larger than that of high DNA concentration indicating at low DNA concentration, the FAL assay performed with lower
precision when the different ambient temperature being tested were compared.
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and 35 at 37°C and 42°C were not evident when P. vivax
DNA only was used. The MMSR assay was also stable
when analysed with P. falciparum DNA only at low
concentration. However, there was degradation of the
PLU and FAL targets at 42°C from D14-D42.
Comparison of MMSR assay to “wet” assay in analysis of
field clinical samples
To further compare the performance of MMSR assay to
the “wet” assay, 180 field clinical samples were analysed
using both assay formulations. The “wet” assay was used as
the reference method which the performance of the MMSR
assay was compared against. The sensitivity of MMSR assay
was calculated as [(number of true positives)/(number of
true positives + number of false negatives)], and specificity
was calculated as the [(number of true negatives)/(number
of true negatives + number of false positives)] as previously
described [8]. The assay performed with 100% sensitivity
and specificity. To further compare the performance
of the two assay formulations using field clinical samples,Spearman’s analysis was performed using CT values
obtained (Figure 3). The statistical analysis revealed that
the pairing was highly effective with p <0.0001. The mean
CT for MMSR assay was 20.67 (95% CI 20.13-21.21) and
for the wet assay was 20.29 (95% CI 19.82-20.77), further
revealing the performance characteristics of these two
assay formulations was highly comparable.
Discussion
This study describes creation of a lyophilized, MMSR
assay for detection of Plasmodium DNA targets and
an endogenous control. The initial characterization
compared the performance of the MMSR assay to that of
the “wet” assay which was recently published [16]. Some
of the characteristics that were initially assessed include
assay efficiency, precision and sensitivity. The efficiency of
a PCR reaction is critical because it is a measure of the
overall performance of the assay whereas precision can
be used to monitor the accuracy of template and reagent
pipetting, homogeneity of template, and instrument
performance. The MMSR assay performed with high
Figure 3 MMSR assay versus wet assay in analysis of field
clinical samples. Spearman’s analysis between analysis of clinical
samples using MMSR and wet assay revealed there was a statistically
significant correlation between the two assays.
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than the “wet” assay. The improved sensitivity seen
with lyophilized assay can be explained by the fact
that when manufacturing these assays, the Taq DNA
polymerase used is glycerol free. This allows for
higher concentration of Taq DNA polymerase to be
used per reaction in the lyophilized assay than in the “wet”
assay. Furthermore, the way the lyophilized assay is
formulated allows for adjustments of other components in
the lyophilization master mix (by addition or subtraction)
such as various salts and additives that cannot knowledgeably
be changed in commercial off-the-shelf master mix
(such as QuantiTect) used in the “wet” assay. These
performance characteristics of the MMSR assay demon-
strated confidence that conversion of the “wet” assay into
lyophilized assay did not compromise the performance of
the malaria multiplex assay.
The ready-to-use lyophilized qPCR assays mitigates
some of the qPCR limitations. They simplify the workflow,
reduce variability, reduce risk of contamination, and
remove the need for cold-chain. Stability of lyophilized
PCR assays and the removal of the need for cold-chain is
critical as qPCR continues to become an important
diagnostic tool in resource constraint environment. It also
removes the challenges and cost associated with shipping
and storage of qPCR reagents. This study focused on
testing the stability of the MMSR assay in different
ambient temperature conditions. Previous studies have
demonstrated stability of lyophilized PCR assays that last
beyond six months at temperatures ranging between 20
and 24°C, and three months at 37°C [20-23]. The MMSR
assay was stable in all test conditions when high
DNA concentration was used for analysis over the
entire period which the assay was tested. However, at low
DNA concentration, some of the assay targets were
degraded when analysed using mixed DNA at elevated
temperatures. The RNaseP assay remained stable in all
test conditions. Using the Q10 method, the stability ofmedical devices is tested by storing the device at elevated
temperature and monitoring stability overtime [19]. The
longest duration that the thermostabilized PCR maintains
its activity is calculated to determine the shelf-life of the
device [19,21]. In this study, the thermostability of MMSR
assay was tested for 42 days, which is approximately
1.5 months. At 37°C, the MMSR assay was stable at all the
test conditions analysed using P. falciparum, P. vivax or
mixed DNA, both at low and high DNA concentrations.
The only exception was when only one of the three
replicate amplified on D21 and on D28, when mixed
DNA was used for analysis. The thermostability of the
MMSR assay was calculated at 37°C for 1.5 months, which
the shelf life for MMSR assay at ambient temperature RT
of 22°C was estimated to be 5 months when mathematically
correlated with its stability at 37°C. The stability of MMSR
assay is important because it clearly demonstrates that the
MMSR assay can be transported and stored without the
need for cold-chain, a useful and critical attribute especially
for distributing this test to remote or distance regions
without the concern of degradation of the reagents or
decreased reliability of the test. Currently, the military
malaria programme has footprint in the USA, Southeast
Asia, South America and Africa. The MMSR assay is
currently being used to support studies in some of
these locations. The stability of the assay is strategic
because it ensures assay reproducibility regardless of
location which the assay is performed. It also removes
transportation challenges and costs associated with the
need for cold-chain.
To further validate the utility of MMSR assay in field
settings, samples collected from field studies were tested at
USAMRU-K laboratories in Kenya. The MMSR assay used
was over 18 months old, stored at 4°C and transported
from the USA to Kenya without cold-chain. The data
obtained demonstrated that the MMSR assay performed
the same as the “wet” assay, validating the utility of the
MMSR assay in field settings. This further demonstrates
that MMSR assay can easily be developed for personal
qPCR instruments or point-of-care instruments without
concerns of compromising the assay sensitivity.
BioGX Inc, the manufacturer of MMSR assay, has
extensive experience in designing and manufacturing of
lyophilized Sample-Ready™ assays. They provide custom
molecular assay design, development, automation, and
manufacturing services and offers qPCR tests across
diverse applications. For example, in recent news
(posted on BioGX Inc’ website), the US Food and
Drug Administration released a protocol to identify
ruminant DNA in pig-derived crude heparin utilizing
BioGX Inc's real-time PCR-based Ruminant and Porcine
test. In the development of the MMSR assay, two
prototypes of the Sample-Ready™ assays were developed;
pellets and cakes. The pellets form a smooth round
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dispensed at the bottom of the tube. The pellets are easy
to work with because they settle at the bottom of the tube.
Cakes however tend to flake and can be challenging to
work with because of the amount of static developed,
which can lead to loss of the material. BioGX Inc
performed several studies to optimize the cake and
prescribed procedures to control statics. They recom-
mended using the cake formulation because it would
provide a more sensitive and stable product.
In addition to BioGX Inc, there are other companies,
such as GE Life Sciences (Pittsburgh, PA, USA) and
Cepheid (Sunnyvale, CA, USA) that can custom
manufacture lyophilized PCR assays. It is also possible
to custom-make and optimize lyophilized PCR assays
in the laboratory as well. However, this can be a long,
tedious and complex process. For example, in an attempt
to lyophilize an internal positive control RNA to help
ensure the accuracy of the detection of avian influenza
virus RNA by reverse transcription (RT)-PCR and real-time
RT-PCR, Das et al. [20] were forced to lyophilize without
some of the enzymes because of stability concerns.
Klatser et al. describes a complex procedure for
developing of a freeze-dried, lyophilized PCR assay [22].
In 2010, Cheung et al. [24] attempted to custom-make
lyophilized assay for detection of influenza. However, the
lyophilized reagents and the assay condition needed
further optimization to improve the sensitivity and
amplification efficiency. However, when a PubMed search
was done in January 2014, there was no indication such
optimization had been published more than three years
later. Having a company custom-manufacture lyophilized
assay(s) is likely to result in a more optimized, reproducible
product, much more than attempting to custom-make
lyophilized assay in a laboratory due to complexity of the
procedure. However, the lyophilization process is likely to
increase the cost of qPCR assay which is one of the main
concerns of molecular assays. At the current rate, “wet”
assay cost less than one dollar per reaction whereas
lyophilized assay is more than ten dollars per reaction,
increasing the cost of qPCR per reaction by more than
ten-fold. It is therefore critical that the benefits of lyophi-
lized molecular assays are assessed in the context of all the
benefits gained with lyophilization and the cost savings that
come along with it, such as reduced cost in transporting of
reagents and no need for cold-chain.
Conclusion
A stable, lyophilized multiplex assay for detection of
Plasmodium, P. falciparum and P. vivax that is highly
robust and has the same performance characteristics as
the “wet” assay has been developed. Although the
lyophilization process may increase the cost of qPCR, both
assays can be adapted for analysis of samples dependingon the situation and the prevailing circumstances. Most
important, since both formulations have the same
performance characteristics, assays performed using either
of the formulations can be compared. Both lyophilized
and “wet” assays are routinely used for qPCR analysis
at the WRAIR and subordinate commands. Both
formulations have been used in controlled human
malaria infection (CHMI) trials. MMSR assay is especially
critical in CHMI studies where precision, reproducibility
and sensitivity of the qPCR assay are important and cost of
individual assays is not a limiting factor since fewer
samples are analysed compared to field studies. Availability
of alternative formulations of qPCR assay with the same
performance characteristics, each with unique advantages,
offers the flexibility of choosing the most convenient
diagnostic tool from the molecular diagnostics toolkit.
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for each individual assay targets for each test condition at the 7
different time points using DNA at low concentration.
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